[1]

葛均波, 徐永健, 王辰. 内科学[M]. 9版. 北京: 人民卫生出版社, 2018: 680−685.

Ge JB, Xu YJ, Wang C. Internal medicine[M]. 9th ed. Beijing: People's Medical Publishing House, 2018: 680−685.
[2] Rausch-Fan X, Leutmezer F, Willheim M, et al.  Regulation of cytokine production in human peripheral blood mononuclear cell and allergen-specific Th cell clones by 1alpha, 25-dihydroxyvitamin D3[J]. Int Arch Allergy Immunol, 2002, 128(1): 33-41.   doi: 10.1159/000058001
[3] Yasuda T, Okamoto Y, Hamada N, et al.  Serum vitamin D levels are decreased in patients without remission of Graves' disease[J]. Endocrine, 2013, 43(1): 230-232.   doi: 10.1007/s12020-012-9789-6
[4] 蒋宁一.  2016版美国甲状腺协会《甲状腺功能亢进症和其他原因所致甲状腺毒症诊治指南》解读: 核医学部分[J]. 中华核医学与分子影像杂志, 2018, 38(5): 305-309.   doi: 10.3760/cma.j.issn.2095-2848.2018.05.001
Jiang NY.  Interpretation of 2016 American Thyroid Association guidelines for diagnosis and management of huperthyroidism and other causes of thyrotoxicosis: nuclear medicine part[J]. Chin J Nucl Med Mol Imaging, 2018, 38(5): 305-309.   doi: 10.3760/cma.j.issn.2095-2848.2018.05.001
[5] Holick MF, Binkley NC, Bischoff-Ferrari HA, et al.  Evaluation, treatment, and prevention of vitamin D deficiency: an Endocrine Society clinical practice guideline[J]. J Clin Endocrinol Metab, 2011, 96(7): 1911-1930.   doi: 10.1210/jc.2011-0385
[6] 蒋宁一, 林岩松, 关海霞, 等.  131I治疗格雷夫斯甲亢指南(2013版)[J]. 中华核医学与分子影像杂志, 2013, 33(2): 83-94.   doi: 10.3760/cma.j.issn.2095-2848.2013.02.002
Jiang NY, Lin YS, Guan HX, et al.  131I guidelines for Graves' hyperthyroidism (2013 Edition)[J]. Chin J Nucl Med Mol Imaging, 2013, 33(2): 83-94.   doi: 10.3760/cma.j.issn.2095-2848.2013.02.002
[7]

Kristensen B. Regulatory B and T cell responses in patients with autoimmune thyroid disease and healthy controls[J/OL]. Dan Med J, 2016, 63(2): B5177[2019-05-13]. http://europepmc.org/article/MED/26836805.
[8]

Eshaghkhani Y, Sanati MH, Nakhjavani M, et al. Disturbed Th1 and Th2 balance in patients with Graves' disease[J]. Minerva Endocrinol, 2016, 41(1): 28−36.
[9] Kawakami-Tani T, Fukawa E, Tanaka H, et al.  Effect of 1 alpha-hydroxyvitamin D3 on serum levels of thyroid hormones in hyperthyroid patients with untreated Graves' disease[J]. Metabolism, 1997, 46(10): 1184-1188.   doi: 10.1016/S0026-0495(97)90214-6
[10] Chailurkit LO, Aekplakorn W, Ongphiphadhanakul B.  High vitamin D status in younger individuals is associated with low circulating thyrotropin[J]. Thyroid, 2013, 23(1): 25-30.   doi: 10.1089/thy.2012.0001
[11] Zhang Q, Wang Z, Sun M, et al.  Association of high vitamin d status with low circulating thyroid-stimulating hormone independent of thyroid hormone levels in middle-aged and elderly males[J]. Int J Endocrinol, 2014, 2014: 631819-.   doi: 10.1155/2014/631819
[12] Ahn HY, Chung YJ, Cho BY, et al.  Serum 25-hydroxyvitamin D might be an independent prognostic factor for Graves disease recurrence[J]. Medicine (Baltimore), 2017, 96(31): e7700-.   doi: 10.1097/MD.0000000000007700
[13] Bikle D.  Nonclassic actions of vitamin D[J]. J Clin Endocrinol Metab, 2009, 94(1): 26-34.   doi: 10.1210/jc.2008-1454
[14] Rotondi M, Chiovato L.  Vitamin D deficiency in patients with Graves' disease: probably something more than a casual association[J]. Endocrine, 2013, 43(1): 3-5.   doi: 10.1007/s12020-012-9776-y